Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis.

Lennerz J.K., Hurov J.B., White L.S., Lewandowski K.T., Prior J.L., Planer G.J., Gereau IV R.W., Piwnica-Worms D., Schmidt R.E., Piwnica-Worms H. (2010) Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Molecular and cellular biology, 30(21):5043-56.

 PubMed


Genetic targeting of ERK1 suggests a predominant role for ERK2 in murine pain models.

Alter B.J., Zhao C., Karim F., Landreth G.E., Gereau IV R.W. (2010) Genetic targeting of ERK1 suggests a predominant role for ERK2 in murine pain models. The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(34):11537-47.

 PubMed


Activation of metabotropic glutamate receptor 5 in the amygdala modulates pain-like behavior.

Kolber B.J., Montana M.C., Carrasquillo Y., Xu J., Heinemann S.F., Muglia L.J., Gereau IV R.W. (2010) Activation of metabotropic glutamate receptor 5 in the amygdala modulates pain-like behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(24):8203-13.

 PubMed


Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase.

Thors L., Burston J.J., Alter B.J., McKinney M.K., Cravatt B.F., Ross R.A., Pertwee R.G., Gereau IV R.W., Wiley J.L., Fowler C.J. (2010) Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. British journal of pharmacology, 160(3):549-60.

 PubMed


RET signaling is required for survival and normal function of nonpeptidergic nociceptors.

Golden J.P., Hoshi M., Nassar M.A., Enomoto H., Wood J.N., Milbrandt J., Gereau IV R.W., Johnson Jr. E.M., Jain S. (2010) RET signaling is required for survival and normal function of nonpeptidergic nociceptors. The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(11):3983-94.

 PubMed